Brigham AI researcher and radiation oncologist Danielle S. Bitterman, MD, is part of the team behind TRIPOD-LLM, a tool that standardizes reporting guidelines for authors of studies focused on biomedical and healthcare large language models.

From novel laboratory research that enables scientists to define pancreatic cancer cells better to new clinical approaches that expedite postsurgical recovery, Dana-Farber Brigham Cancer Center is steadily advancing the diagnosis and management of pancreatic cancers. Sahar Nissim, MD, PhD, and Thomas E. Clancy, MD, FACS, elaborate.

In a study published in Science Advances, investigators reported for the first time that Merkel cell carcinoma cells express programmed cell death 1 (PD-1). This research has crucial implications for the potential development of new combination therapies for the disease, as senior author Tobias Schatton, PharmD, PhD, explains.

Meet Anthony D’Amico, MD, PhD, Chief of Genitourinary Radiation Oncology at Dana-Farber Brigham Cancer Center, and Eleanor Theresa Walters Distinguished Chair in Radiation Oncology, renowned for his exceptional contributions to cancer care, particularly in genitourinary cancer.

Brigham and Women’s Hospital and Dana-Farber Cancer Institute radiologists and radiation oncologists are at the forefront of harnessing the power of AI to change patients’ lives, as reflected in several recent research projects. Learn about the work of Michael H. Rosenthal, MD, PhD, Benjamin H. Kann, MD, Martin T. King, MD, PhD, and Danielle S. Bitterman, MD.

Danielle S. Bitterman, MD, is the corresponding author of a study that assessed the ability of ChatGPT to recommend guidelines-based cancer treatments. She and her colleagues found the chatbot provided inappropriate recommendations in about one-third of cases, indicating the need to raise awareness about its limitations.